在患有严重心力衰竭的住院患者中,经过神经肌肉电刺激后提高了表现
Theresa Maria Betz1, Hannes Kinitz1, Isabel Kristen1
1Department of Sports Medicine, Medical Clinic, University Hospital Heidelberg, Im Neuenheimer Feld 410, Heidelberg 69120, Germany.
ESC heart failure
|February 19, 2026
概括
神经肌肉电刺激 (NMES) 在住院的严重心力衰竭患者中安全改善了功能表现. 这种疗法,当添加到物理治疗时,显著提高了StimFIT5-Score,特别是在不太适合的个体中.
科学领域:
- 心脏病学 心脏病学
- 康复医学 康复医学 康复医学
- 生物医学工程 生物医学工程
背景情况:
- 严重心力衰竭患者经常经历缩症,导致运动能力下降.
- 住院治疗可能会加剧这些患者的肌肉损失和功能衰退.
- 现有的治疗方法可能无法完全解决严重心力衰竭中的功能缺陷.
研究的目的:
- 评估神经肌肉电刺激 (NMES) 在住院重症心力衰竭患者的安全性和有效性.
- 评估NMES作为物理治疗的辅助对功能表现的影响.
- 为了研究心脏电子设备患者的NMES效应.
主要方法:
- 30名严重心力衰竭患者被随机分配到对照组 (仅物理治疗) 或刺激组 (物理治疗+2周NMES).
- 功能性能的测量使用5个测试,汇总成StimFIT5-Score,在基线和2周.
- 监测了心脏器械患者的安全性,包括电磁干扰. 抑郁症状 (PHQ9-Score) 也被评估.
主要成果:
- 在心脏器械患者中,NMES是安全的,没有不良事件或电磁干扰.
- 与对照组相比,NMES组在StimFIT5-Score中显示出显著更大的改善.
- 改善在最不适合的患者中最为明显,在6分钟步行测试和坐立测试中获得了显著的收益.
结论:
- 对于住院的严重心力衰竭患者,包括使用心脏电子设备的患者,NMES是一种安全的治疗选择.
- 将NMES添加到物理治疗中显著提高了功能表现,通过StimFIT5-Score进行测量.
- 无论性别,NMES的益处在基线功能能力较低的患者中最为显著.
相关概念视频
01:26Heart Failure Drugs: Inotropic Agents
2.0K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
2.0K
01:29Heart Failure II: Pathophysiology
2.1K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
2.1K
01:30Heart Failure V: Medical Management
641
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
641
01:22Heart Failure VI: Adjunct Therapies
635
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
635
01:30Heart Failure VII: Nursing Interventions
807
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
807
01:30Cardiomyopathy II: Dilated Cardiomyopathy
798
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
798